Discover and read the best of Twitter Threads about #EGFRex20
Most recents (3)
#WCLC20 CHRYSALIS trial results with amivantamab in #EGFRex20 NSCLC post-platinum based chemotherapy presented by @JSabari. Amivantamab has FDA breakthrough designation for this indication. @IASLC #LCSM @OncoAlert 
#WCLC20 Highly anticipated results of oral TKI mobocertinib (TAK-788) in #EGFRex20 mutant NSCLC after prior platinum based chemotherapy. Huge unmet need and as @Jbauml reported at this meeting, likely underdiagnosed. #LCSM @IASLC @OncoAlert
#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM
#OncoAlert #AACR20 Dose escalation of TAK-788 (mobocertinib) established MTD of 160mg qday. DLTs were 1 case each of grade 3 diarrhea, grade 3 mucositis, grade 3 pneumonitis, and grade 5 (fatal) pneumonitis. Study then enrolled into 7 different baskets to explore efficacy. #LCSM
#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM
